摘要
目的:研究伴t(8;21)的急性髓性白血病(AML)患者近期疗效。方法:30例伴t(8;21)的AML患者中M01例、M226例、M52例、CML-BPI例。26例伴有t(8;21)的M2患者中简单核型异常9例,复杂核型异常17例,取28例正常核型的M2患者为对照,观察染色体核型异常与化疗后完全缓解(CR)率的关系。结果:t(8;21)的非M2患者除1例M5经治疗为CR外,余3例均为NR;t(8;21)的M2患者的CR率(84.6％(22/26))高于正常核型的M2患者(64.3％(18/28))(P>0.05);简单核型异常的M2/t(8;21)患者化疗CR率(94.1％(16/17))高于伴复杂核型异常的M2/t(8;21)患者(66.7％(6/9))(P>0.05)。结论:t(8;21)的M2患者预后较好。而伴复杂核型M2/1(8;21)患者疗效相对较差。
Aim: To elucidate the therapeutic effect of acute myeloid leukemia (AML) with t(8;21). Method: Karyo-types of 30 patients with AML were analyzed with the R-banding techniques. Results: Of the AML patients with t(8;21) , 84% (26/30) was M2 subtype. The complete remission (CR) rate in the group of M2 with t(8;21) was higher than that in the group of M2 with normal karyotypes (84. 6% (22/26) vs 64. 3% (18/28) ). The CR rate was higher in the group of simple karyotype than that in the group of complicated karyotypes (94. 1% (16/17) vs 66.7% (3/9)). Conclusions: The patients with M2/t(8;21) will survive longer. M2/t(8;21) with complicated karyotypes may prognose poor therapeutic effect.
出处
《郑州大学学报（医学版）》
CAS
北大核心
2004年第2期304-305,共2页
Journal of Zhengzhou University(Medical Sciences)
关键词
t(8
21)
白血病
髓性
急性
疗效
t(8
21 )
leukemia, myeloid , acute
therapeutic effect
